Literature DB >> 17101264

Macrolide resistance rates in respiratory pathogens in Slovenia following reduced macrolide use.

Milan Cizman1, Bojana Beović, Katja Seme, Metka Paragi, Iztok Strumbelj, Manica Müller-Premru, Silva Cad-Pecar, Marko Pokorn.   

Abstract

The aim of this study was to investigate the association between decreased use of macrolides and resistance of common respiratory pathogens in Slovenia from 1999 to 2004. Over a 6-year period the consumption of macrolides in Slovenia decreased by 21.3%, from 3.81 defined daily doses/1000 inhabitants per day (DID) to 3.0 DID. The use of short-acting, intermediate-acting and long-acting subclasses of macrolides decreased by 50%, 18% and 13%, respectively. In the same period, resistance of invasive strains of Streptococcus pneumoniae increased from 4.6% to 11.1% and resistance of non-invasive strains of S. pneumoniae and Streptococcus pyogenes increased from 12.8% to 20.2% and from 7.4% to 12.5%, respectively. Resistance increased significantly more in children than in adults (P=0.05) and was significantly correlated with increased use of intermediate-acting macrolides (r=0.94 for non-invasive S. pneumoniae and r=0.96 for S. pyogenes) in children. Resistance of Haemophilus influenzae and Moraxella catarrhalis was low and did not change. In children and adults, the emergence and spread of multidrug-resistant strains of invasive S. pneumoniae was observed. The decline in total macrolide use was not paralleled by reduced macrolide resistance rates of S. pyogenes and S. pneumoniae during the 6-year period. There was a strong correlation between the use of intermediate-acting macrolides and macrolide resistance of S. pyogenes and S. pneumoniae in children. Further reduction in the use of intermediate- and long-acting macrolides should be encouraged.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17101264     DOI: 10.1016/j.ijantimicag.2006.07.023

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  4 in total

Review 1.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Antimicrobial drug use and macrolide-resistant Streptococcus pyogenes, Belgium.

Authors:  Liesbet Van Heirstraeten; Samuel Coenen; Christine Lammens; Niel Hens; Herman Goossens; Surbhi Malhotra-Kumar
Journal:  Emerg Infect Dis       Date:  2012-09       Impact factor: 6.883

3.  Macrolide susceptibility and serotype specific macrolide resistance of invasive isolates of Streptococcus pneumoniae in Germany from 1992 to 2008.

Authors:  Matthias Imöhl; Ralf René Reinert; Christina Mutscher; Mark van der Linden
Journal:  BMC Microbiol       Date:  2010-11-25       Impact factor: 3.605

4.  Decline in macrolide resistance rates among Streptococcus pyogenes causing pharyngitis in children isolated in Italy.

Authors:  G Gherardi; D Petrelli; M C Di Luca; F Pimentel de Araujo; P Bernaschi; A Repetto; J Bellesi; L A Vitali
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-05-30       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.